851 related articles for article (PubMed ID: 33003964)
1. Safely Administering Potential QTc Prolonging Therapy Across a Large Health Care System in the COVID-19 Era.
Saleh M; Gabriels J; Chang D; Fishbein J; Qiu M; Mountantonakis SE; Epstein LM;
Circ Arrhythm Electrophysiol; 2020 Nov; 13(11):e008937. PubMed ID: 33003964
[TBL] [Abstract][Full Text] [Related]
2. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
Saleh M; Gabriels J; Chang D; Soo Kim B; Mansoor A; Mahmood E; Makker P; Ismail H; Goldner B; Willner J; Beldner S; Mitra R; John R; Chinitz J; Skipitaris N; Mountantonakis S; Epstein LM
Circ Arrhythm Electrophysiol; 2020 Jun; 13(6):e008662. PubMed ID: 32347743
[TBL] [Abstract][Full Text] [Related]
3. Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients.
Eftekhar SP; Kazemi S; Barary M; Javanian M; Ebrahimpour S; Ziaei N
Cardiovasc Ther; 2021; 2021():6683098. PubMed ID: 33688374
[TBL] [Abstract][Full Text] [Related]
4. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin.
Chorin E; Wadhwani L; Magnani S; Dai M; Shulman E; Nadeau-Routhier C; Knotts R; Bar-Cohen R; Kogan E; Barbhaiya C; Aizer A; Holmes D; Bernstein S; Spinelli M; Park DS; Stefano C; Chinitz LA; Jankelson L
Heart Rhythm; 2020 Sep; 17(9):1425-1433. PubMed ID: 32407884
[TBL] [Abstract][Full Text] [Related]
5. Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.
O'Connell TF; Bradley CJ; Abbas AE; Williamson BD; Rusia A; Tawney AM; Gaines R; Schott J; Dmitrienko A; Haines DE
JACC Clin Electrophysiol; 2021 Jan; 7(1):16-25. PubMed ID: 33478708
[TBL] [Abstract][Full Text] [Related]
6. Cardiac Corrected QT Interval Changes Among Patients Treated for COVID-19 Infection During the Early Phase of the Pandemic.
Rubin GA; Desai AD; Chai Z; Wang A; Chen Q; Wang AS; Kemal C; Baksh H; Biviano A; Dizon JM; Yarmohammadi H; Ehlert F; Saluja D; Rubin DA; Morrow JP; Avula UMR; Berman JP; Kushnir A; Abrams MP; Hennessey JA; Elias P; Poterucha TJ; Uriel N; Kubin CJ; LaSota E; Zucker J; Sobieszczyk ME; Schwartz A; Garan H; Waase MP; Wan EY
JAMA Netw Open; 2021 Apr; 4(4):e216842. PubMed ID: 33890991
[TBL] [Abstract][Full Text] [Related]
7. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
Diaz-Arocutipa C; Brañez-Condorena A; Hernandez AV
Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):694-706. PubMed ID: 33772933
[TBL] [Abstract][Full Text] [Related]
8. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).
Mercuro NJ; Yen CF; Shim DJ; Maher TR; McCoy CM; Zimetbaum PJ; Gold HS
JAMA Cardiol; 2020 Sep; 5(9):1036-1041. PubMed ID: 32936252
[TBL] [Abstract][Full Text] [Related]
9. QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection.
Bun SS; Taghji P; Courjon J; Squara F; Scarlatti D; Theodore G; Baudouy D; Sartre B; Labbaoui M; Dellamonica J; Doyen D; Marquette CH; Levraut J; Esnault V; Bun SS; Ferrari E
Clin Pharmacol Ther; 2020 Nov; 108(5):1090-1097. PubMed ID: 32588427
[TBL] [Abstract][Full Text] [Related]
10. Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase.
Saint-Gerons DM; Tabarés-Seisdedos R
Eur J Clin Pharmacol; 2021 Oct; 77(10):1513-1521. PubMed ID: 33938974
[TBL] [Abstract][Full Text] [Related]
11. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
Sarayani A; Cicali B; Henriksen CH; Brown JD
Res Social Adm Pharm; 2021 Feb; 17(2):483-486. PubMed ID: 32327397
[TBL] [Abstract][Full Text] [Related]
12. Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.
Carron J; Sharif Z; Hussein H; Kennedy M; McAdam B; Sheahan R
Ir J Med Sci; 2021 Feb; 190(1):403-409. PubMed ID: 32627127
[TBL] [Abstract][Full Text] [Related]
13. Effects of cardiac toxicity of combination therapy with hydroxychloroquine and azithromycin in COVID-19 patients.
Yendrapalli U; Ali H; Green JL; Edwards J
J Infect Public Health; 2021 Nov; 14(11):1668-1670. PubMed ID: 34627063
[TBL] [Abstract][Full Text] [Related]
14. Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin.
Cipriani A; Zorzi A; Ceccato D; Capone F; Parolin M; Donato F; Fioretto P; Pesavento R; Previato L; Maffei P; Saller A; Avogaro A; Sarais C; Gregori D; Iliceto S; Vettor R
Int J Cardiol; 2020 Oct; 316():280-284. PubMed ID: 32439366
[TBL] [Abstract][Full Text] [Related]
15. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring.
Ramireddy A; Chugh H; Reinier K; Ebinger J; Park E; Thompson M; Cingolani E; Cheng S; Marban E; Albert CM; Chugh SS
J Am Heart Assoc; 2020 Jun; 9(12):e017144. PubMed ID: 32463348
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.
Padilla S; Telenti G; Guillén L; García JA; García-Abellán J; Ding C; Mora A; García-Pachón E; Gutiérrez F; Masiá M;
Int J Antimicrob Agents; 2020 Oct; 56(4):106142. PubMed ID: 32853675
[TBL] [Abstract][Full Text] [Related]
17. Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Sivapalan P; Ulrik CS; Bojesen RD; Lapperre TS; Eklöf JV; Håkansson KEJ; Browatzki A; Tidemansen C; Wilcke JT; Janner J; Gottlieb V; Meteran H; Porsbjerg C; Madsen BL; Moberg M; Pedersen L; Benfield TL; Lundgren JD; Knop FK; Biering-Sørensen T; Ghanizada M; Sonne TP; Bødtger UCS; Jensen SG; Rasmussen DB; Brøndum E; Tupper OD; Sørensen SW; Alstrup G; Laursen CB; Møller UW; Sverrild A; Jensen JS
Trials; 2020 Jun; 21(1):513. PubMed ID: 32522282
[TBL] [Abstract][Full Text] [Related]
18. Torsades de pointes in SARS-CoV-2 (COVID-19) pneumonia: medicine reconciliation and careful monitoring of QTc interval may help prevent cardiac complications.
Aslam W; Lamb CR; Ali N
BMJ Case Rep; 2021 Mar; 14(3):. PubMed ID: 33762277
[TBL] [Abstract][Full Text] [Related]
19. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.
Rosenberg ES; Dufort EM; Udo T; Wilberschied LA; Kumar J; Tesoriero J; Weinberg P; Kirkwood J; Muse A; DeHovitz J; Blog DS; Hutton B; Holtgrave DR; Zucker HA
JAMA; 2020 Jun; 323(24):2493-2502. PubMed ID: 32392282
[TBL] [Abstract][Full Text] [Related]
20. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.
Chorin E; Dai M; Shulman E; Wadhwani L; Bar-Cohen R; Barbhaiya C; Aizer A; Holmes D; Bernstein S; Spinelli M; Park DS; Chinitz LA; Jankelson L
Nat Med; 2020 Jun; 26(6):808-809. PubMed ID: 32488217
[No Abstract] [Full Text] [Related]
[Next] [New Search]
